Sironax' lead RIPK1 drug, SIR0365, has completed two phase 1b studies including one looking at its potential as a treatment for severe hyperinflammation associated with COVID-19 infections, while ...

Institute of Cancer Research UK has identified proteolysis targeting chimeras (PROTACs) comprising a Von Hippel-Lindau disease tumor suppressor (VHL) binding moiety coupled to a receptor-interacting ...